Stay updated with breaking news from Cybin Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Vancouver, British Columbia--(Newsfile Corp. - June 7, 2024) - Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) ("Numinus" or the "Company"), a mental health care company advancing traditional and innovative
Numinus Wellness Inc. , a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, wishes to...
FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision.
- Amir Inamdar, Chief Medical Officer, to appear on panel discussions on June 5 and June 8 - - Ellen James, Director, Clinical Development, to present abstract titled "SPL026 (DMT fumarate) in combination
HC Wainwright reissued their buy rating on shares of Cybin (NYSE:CYBN – Free Report) in a research report report published on Thursday, Benzinga reports. The brokerage currently has a $5.00 price objective on the stock. HC Wainwright also issued estimates for Cybin’s FY2029 earnings at $0.26 EPS. Cybin Stock Down 0.6 % NYSE:CYBN opened at […]